Liaoning Cancer Hospital & Insitut
Welcome,         Profile    Billing    Logout  
 0 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Danbo
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting
3
498
RoW
QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
METASTATIC CERVICAL CANCER
09/24
07/25
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting
2
196
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
12/21
04/22
PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
AK104-218, NCT05932212: AK104 for Recurrent or Metastatic Vulvar Cancer

Recruiting
2
20
RoW
AK104, Cadonilimab, AK104+ Paclitaxel+Cisplatin or Carboplatin
Akeso
Vulvar Cancer
12/25
12/25
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05773820: A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

Recruiting
1/2
210
RoW
WJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd., Sponsor GmbH
Advanced Solid Tumors
04/26
05/26
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Danbo
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting
3
498
RoW
QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
METASTATIC CERVICAL CANCER
09/24
07/25
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting
2
196
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
12/21
04/22
PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
AK104-218, NCT05932212: AK104 for Recurrent or Metastatic Vulvar Cancer

Recruiting
2
20
RoW
AK104, Cadonilimab, AK104+ Paclitaxel+Cisplatin or Carboplatin
Akeso
Vulvar Cancer
12/25
12/25
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05773820: A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

Recruiting
1/2
210
RoW
WJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd., Sponsor GmbH
Advanced Solid Tumors
04/26
05/26
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/24
12/24

Download Options